Implantica presents the third quarter 2022 on November 15 at 15:00 CET
09 Nov 2022
VADUZ, Liechtenstein, Nov. 9, 2022 /PRNewswire/ --
Implantica AG (publ) invites investors to a presentation of the third quarter 2022 at 15:00 CET on November 15. The interim report for the third quarter will be published at 8:00 a.m. CET on the same day.
The presentation will be in English via an audiocast with teleconference:
Conference call dial-in:
Sweden: +46 8 505 583 57
United Kingdom: +44 3333 009273
United States: +1-646-722-4903
Webcast:
https://ir.financialhearings.com/implantica-q3-2022
Speakers:
CEO Peter Forsell
CFO Andreas Öhrnberg
VP Operations & IR Nicole Pehrsson
For further information, please contact:
Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49
[email protected]
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, [email protected]
The information was sent for publication, through the agency of the contact person set out above, on November 9, 2022 at 3:30 p.m. CET.
About Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica's lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
The following files are available for download:
SOURCE Implantica
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.